REGULATORY

Chuikyo Approves Listing of Temcell and HeartSheet, First Two Regenerative Medicine Products

November 19, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) approved the listing of two regenerative medicine products at a general meeting on November 18. The two products are JCR Pharmaceuticals’ Temcell HS Injection, which was priced using NHI drug pricing rules, and…

To read the full story

Terumo Debuts Cell-Based Heart Failure Therapy HeartSheet
May 31, 2016
JCR to Launch Cell Therapy for Post-Transplant Complication in February
November 30, 2015
Viekirax Price, Peak Sales Forecast Called into Question
November 19, 2015
Chuikyo OKs Viekirax, Other Drugs for NHI Price Listing on Nov. 26
November 19, 2015

REGULATORY

Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
MHLW Starts Technical Review of OTC-Like Drug Charge Exemptions
June 29, 2026
Takeda to Shift Immunoglobulin Production to 10% Formulation
June 29, 2026
Japan’s Immunoglobulin Self-Sufficiency Rate Falls Below 60%
June 29, 2026
MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
June 29, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…